Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

Brokers Offer Predictions for Avivagen Inc.'s FY2024 Earnings (OTCMKTS:VIVXF)

Defense World ·  {{timeTz}}

Avivagen Inc. (OTCMKTS:VIVXF – Get Rating) – Investment analysts at Zacks Small Cap issued their FY2024 earnings per share (EPS) estimates for Avivagen in a note issued to investors on Wednesday, August 31st. Zacks Small Cap analyst D. Bautz forecasts that the company will earn ($0.02) per share for the year. The consensus estimate for Avivagen's current full-year earnings is ($0.07) per share.

Get Avivagen alerts:

Avivagen Stock Performance

Shares of VIVXF opened at $0.13 on Thursday. The company has a market capitalization of $9.33 million, a price-to-earnings ratio of -1.40 and a beta of 0.13. The stock has a 50 day moving average of $0.14 and a 200 day moving average of $0.15. Avivagen has a 12 month low of $0.12 and a 12 month high of $0.38.

Avivagen (OTCMKTS:VIVXF – Get Rating) last issued its quarterly earnings results on Wednesday, June 15th. The company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02). The business had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.23 million.

About Avivagen

(Get Rating)

Avivagen Inc, a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr.

Featured Articles

  • Get a free copy of the StockNews.com research report on Avivagen (VIVXF)
  • Could Nike Stock be Oversold, but Still Overvalued?
  • Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
  • Will Royal Caribbean's Broadband Partnership Drive Revenue?
  • Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
  • DocuSign Has Important Issues to Address When it Reports Earnings

Receive News & Ratings for Avivagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avivagen and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.